Skip to content
PreclinicalResearch compoundLimited evidence

PPAP

Experimental brain-stimulating compound studied only in animals and never tested in humans.

NootropicDopaminergicDopaminergicNeuroprotectionDopamineNorepinephrine

Pharmacology

ClassDopaminergic · Neuroprotection
Primary targetEnhancement of impulse-coupled catecholamine release (CAE)
Targets3 receptor targets
Half-lifeNo human pharmacokinetic data
OnsetNo human data
EvidenceLimited evidence
Affected systemsDopamineNorepinephrine

Contents

DETAILED OVERVIEW

What is PPAP?

PPAP is an experimental compound, a relative of the substance deprenyl. It was developed by Hungarian researchers in the late 1980s. It is not approved as a medicine anywhere and is sold as a research chemical; because its structure is related to amphetamine, it may be a controlled substance in some countries, and in competitive sport it may fall under the banned group of stimulants.

In animal studies, nerve cells that use dopamine and noradrenaline released more of these messengers when stimulated. This works differently from amphetamine, which forces them out. PPAP does not block the enzyme MAO and is not turned into amphetamine. It improved learning in rodents. It has never been tested in humans, so its safety is unknown; in theory it could cause a racing heartbeat, higher blood pressure, anxiety, insomnia and dependence.

Mechanism

Catecholaminergic activity enhancer (CAE), non-MAO-inhibiting

Evidence

Preclinical only (no human data)

Legal status

Unapproved; controlled in several countries

Receptor profile

  • Catecholaminergic activity enhancement (CAE)Strong
  • Catecholamine reuptake (DAT/NET)Moderate
  • Neuronal survival signalingModerate

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • No human safety data: the compound has never been tested in humans, all evidence comes from rodent studies
  • Possible overstimulation: anxiety, restlessness, insomnia from the heightened catecholaminergic tone
  • Increased heart rate and elevated blood pressure, as expected from sympathomimetic/stimulant agents
  • Theoretical addiction and abuse potential via dopaminergic reinforcement, though lower than amphetamine
  • Unknown long-term safety and incomplete toxicity profile in humans

Contraindications · 5

  • Pregnancy and breastfeeding: safety not established, avoid
  • Cardiovascular disease, arrhythmia, uncontrolled hypertension: the sympathomimetic effect may worsen them
  • Anxiety disorders, panic disorder: the stimulant effect may aggravate symptoms
  • Avoid combining with MAO inhibitors and other serotonergic/adrenergic agents due to catecholaminergic overload risk
  • Not an approved medicine; experimental research chemical, not recommended without clinical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

PPAP is an experimental research compound, originally developed in the late 1980s as a relative of deprenyl, designed to boost dopamine and noradrenaline signaling in the brain without turning into amphetamine or acting as an MAO inhibitor. In animal studies it improved learning and protected neurons from catecholamine depletion, which is why researchers speculated it might be useful for ADHD, depression, or neurodegenerative conditions. It's worth knowing there is essentially no human data on it, so it remains a scientifically interesting but largely untested molecule.

Telegram

Have a question about PPAP?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC14H23N
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.